Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?
To the Editor, BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are classified as polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The JAK2V617F mutation is present in approximately 95% of patients with PV and in 50%-60% of those with ET or PMF. The thrombopoietin receptor (MPL) exon 10 mutation has been identified in 3% of ET and 7% of PMF patients [1] . Somatic mutations have been described in the calreticulin (CALR) gene of 20% and 25% of patients with ET and PMF, respectively [2] . Detection of one of these 'driver' MPN somatic mutations, along with any co-mutations in an epigenetic gene, indicates a high risk for disease progression or AML transformation [3] .
Although MPN patients with double co-mutations of 'driver' genes have been identified in a few recent studies, 'double-hit' states are still not investigated for clinical outcomes. The reason for the lack of testing of "double-hit" states is that current testing methodology recommends sequential analysis for driver mutations, with completion of testing as soon as one of the mutations is detected [4] .
In this study, we examined 1541 whole blood samples of patients with suspected MPN using a parallel algorithm to detect all driver mutations in the JAK2, MPL and CALR genes. Identification of the JAK2V617F and CALR mutations (c.1092_1143del52 and c.1154_1155insTTGTC) was performed using an 'in house' allele-specific PCR-RT kit [5] with a sensitivity of 0.01%. Detection of MPL (W515L and W515K) mutations was performed by allele-specific PCR-RT as previously described [6] . PCR-RT amplifications were conducted using CFX96 (Bio-Rad, USA). Data analysis was performed using the open source statistical programming language R. Meta-analysis was performed with Comprehensive Meta-Analysis Version 2.0 for Windows (Biostat). The study was carried out in full accordance with the Ethical Principles of the Declaration of Helsinki and was approved by the local Ethics Committee for Krasnoyarsk Regional Clinical Hospital.
ET and MF were diagnosed in 108 patients with the CALR or MPL mutations, and 18 of those patients had a double-hit mutation ( Table 1 ). The JAK2V617F detection rate in the presence of a mutation in CALR was approximately 11% (10 of 91 patients). There were six (60%) type 1 and four (40%) type 2 CALR mutations. The JAK2V617F detection rate in the presence of MPL mutations was approximately 47% (eight of 17 patients). It is interesting that the rate of cases with MPL and JAK2 co-mutations was higher than the rate of cases with CALR and JAK2 co-mutations (p = 0.03, χ 2 = 4.32). Several other studies have indicated the presence of 'double hits' mutations as well; however, these findings were not discussed in these studies. We combined all known data into a meta-analysis, and this analysis confirmed the differences we observed. It was noteworthy that the JAK2V617F and MPL co-mutation occurred at a higher frequency than the JAK2V617F and CALR co-mutation variant (Figure 1) .
These results support the hypothesis of an adaptive role for mutations in somatic cell evolution [7] . As a hypothetical assumption, when myeloproliferative progenitor clones are exposed to growth factors and a microenvironment of proinflammatory cytokines, the probability for mutations occurring in highly expressed genes of the MPL-JAK2 signaling pathway may be increased. For example, this effect can be mediated via nucleic acid editing and single nucleotide substitutions at 'hot spots' in the genome. By contrast, insertion or deletion resulting in a +1 frameshift in the reading frame for the translation of the carboxyl-terminus of CALR is more randomly associated with JAK2V617F. Interestingly, the 46/1 JAK2 haplotype was mainly associated with the emergence JAK2V617F and MPL W515 L/K, but not with CALR co-mutations [8] .
Another aspect of our study is the possibility of reviewing the existing laboratory diagnostic algorithm for MPNs. Parallel testing for the detection of all MPN driver somatic mutations will help to differentiate 'double-hit' subgroups because patients may differ in the progression of the disease, which is a manifestation of clonal heterogeneity [9] . Further studies need to be carried out to validate clinical effect of this clonal heterogeneity. Meta-analysis of the data when both variants of the double-hit mutations in the driver genes were tested. 
